VEGF receptor 2 blockade leads to renal cyst formation in mice

Kidney International

Volumn 69, Issue 10, 2006, Pages 1741-1748

  McGrath Morrow, S ^a,d   Cho, C ^a   Molls, R ^b   Burne Taney, M ^b   Haas, M ^a   Hicklin, D J ^c   Tuder, R ^a   Rabb, H ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

DC101; Renal cysts; VEGFR 2 blockade

Indexed keywords

DC101 ANTIBODY; POLYCYSTIN 1; POLYCYSTIN 2; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONGENITAL BLOOD VESSEL MALFORMATION; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; GENE MUTATION; GLOMERULUS; INFLAMMATION; KIDNEY CYST; KIDNEY DEVELOPMENT; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE EPITHELIUM; MOUSE; NEWBORN; NONHUMAN; PERINATAL PERIOD; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEINURIA; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES, CYSTIC; MICE; MICE, INBRED STRAINS; SIGNAL TRANSDUCTION; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33646692923     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000314     Document Type: Article

References (32)

1. Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716.
2. Kitamoto Y, Tokunaga H, Tomita K. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J Clin Invest 1997; 99: 2351-2357.
3. Gerber HP, Hillan KJ, Ryan AM et al. VEGF is required for growth and survival in neonatal mice. Development 1999; 126: 1149-1159.
4. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017.
5. Sugimoto H, Hamano Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605-12608.
6. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
7. Kanellis J, Fraser S, Katerelos M, Power DA. Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. Am J Physiol Renal Physiol 2000; 278: F905-F915.
8. Senthil D, Choudhury GG, McLaurin C, Kasinath BS. Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy. Kidney Int 2003; 64: 468-479.
9. Tufro A, Norwood VF, Carey RM, Gomez RA. Vascular endothelial growth factor induces nephrogenesis and vasculogenesis. J Am Soc Nephrol 1999; 10: 2125-2134.
10. Largo R, Gomez-Garre D, Soto K et al. Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria. Hypertension 1999; 33: 732-739.
11. Vio CP, Jeanneret VA. Local induction of angiotensin-converting enzyme in the kidney as a mechanism of progressive renal diseases. Kidney Int Suppl 2003; 86(suppl): S57-S63.
12. Villegas G, Lange-Sperandio B, Tufro A. Autocrine and paracrine functions of vascular endothelial growth factor (VEGF) in renal tubular epithelial cells. Kidney Int 2005; 67: 449-457.
13. Mattot V, Moons L, Lupu F et al. Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J Am Soc Nephrol 2002; 13: 1548-1560.
14. Druid H, Nilsson I, Rammer L, Skude G. Effect of anticoagulation on renal function and protein excretion in experimental acute ischemic renal failure. Renal Fail 1999; 21: 647-657.
15. Wen JG, Frokiaer J, Zhao JB et al. Severe partial ureteric obstruction in newborn rats can produce renal dysplasia. BJU Int 2002; 89: 740-745.
16. Yoo KH, Wolstenholme JT, Chevalier RL. Angiotensin-converting enzyme inhibition decreases growth factor expression in the neonatal rat kidney. Pediatr Res 1997; 42: 588-592.
17. Sugimoto H, Hamano Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605-12608.
18. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
19. Tejera N, Gomez-Garre D, Lazaro A et al. Persistent proteinuria upregulates angiotensin II type 2 receptor and induces apoptosis in proximal tubular cells. Am J Pathol 2004; 164: 1817-1826.
20. Kocaman O, Oflaz H, Yekeler E et al. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004; 43: 854-860.
21. Gieteling EW, Rinkel GJ. Characteristics of intracranial aneurysms and subarachnoid haemorrhage in patients with polycystic kidney disease. J Neurol 2003; 250: 418-423.
22. Saadi-Kheddouci S, Berrebi D, Romagnolo B et al. Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene. Oncogene 2001; 20: 5972-5981.
23. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-1851.
24. Weis S, Shintani S, Weber A et al. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 2004; 113: 885-894.
25. Wheelock MJ, Johnson KR. Cadherin-mediated cellular signaling. Curr Opin Cell Biol 2003; 15: 509-514.
26. Zhou Y, McMaster M, Woo K et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160: 1405-1423.
27. Carmeliet P, Moons L, Luttun A et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575-583.
28. Autiero M, Waltenberger J, Communi D et al. Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9: 936-943.
29. Son WC. Factors contributory to early death of young CD-1 mice in carcinogenicity studies. Toxicol Lett 2003; 145: 88-98.
30. Hicklin DJ, Witte L, Zhu Z et al. Monoclonal antibody strategies to block angiogenesis. Drug Discov Today 2001; 6: 517-528.
31. + stem cells from bone-marrow microenvironment. Nat Med 2002; 8: 841-849.
32. Prewett M, Huber J, Li Y et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209-5218.